The news of Oppenheimer analyst Jay Olson reiterating an Outperform rating on Amgen and maintaining a $280 price target is positive for the stock. This reaffirms the analyst's confidence in the company's performance and growth potential, which could lead to an increase in investor interest and a potential short-term rise in the stock price.